Oryzon nominates bispecific LSD1/MAOB inhibitor as drug candidate to enter preclinical development in Huntington´s Disease
ORYZON announced today that it is entering preclinical development with its first drug candidate, a first-in-class bispecific Lysine Specific Demethylase 1 (LSD1) and Monoamine oxidase B (MAO-B) inhibitor for the treatment of Huntington disease (HD). These inhibitors increased survival time and improved several behavioral and motor parameters in different transgenic animal models.